

<b>LIST OF REFERENCES CITED BY APPLICANT</b> <i>(Use several sheets if necessary)</i>					ATTY. DOCKET NO.	APPLICATION NO.	
					10412-025	09/709,170	
					APPLICANT		
					Warrell et al.		
FILING DATE November 10, 2000					GROUP	To Be Assigned	
<b>U.S. PATENT DOCUMENTS</b>							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	AA	5,098,890	3/24/92	Gewirtz et al.			
	AB	5,202,429	4/13/93	Tsujimoto et al.			
	AC	5,459,251	10/17/95	Tsujimoto et al.			
	AD	5,734,033	03/31/98	Reed; J			
	AE	5,831,066	06/05/95	Reed; J.			
	AF	6,040,181	03/21/00	Reed; J.			
<b>FOREIGN PATENT DOCUMENTS</b>							
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
	AG	88302617	3/24/88	EU			YES      NO
	AH	WO 94/27426	12/08/94	PCT			
	AI	WO 93/20200	10/14/93	PCT			
	AJ	WO 91/04014	04/04/91	PCT			
<b>OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)</b>							
	AK	Asseline et al, Nucleic acid-binding molecules with high affinity and base sequence specificity: intercalating agents covalently linked to oligodeoxynucleotides. Proc Natl Acad Sci 1984, Jun;81(11):3297-301					
	AL	Bishop JM. The molecular genetics of cancer. Science. 1987 Jan 16;235(4786):305-11.					
	AM	Blake et al, Inhibition of rabbit globin mRNA translation by sequence-specific oligodeoxyribonucleotides. Biochemistry. 1985 Oct 22;24(22):6132-8					
	AN	Boutorin et al., Synthesis of alkylating oligonucleotide derivatives containing cholesterol or phenazinium residues at their 3'-terminus and their interaction with DNA within mammalian cells. FEBS Lett. 1989 Aug 28;254(1-2):129-32					
	AO	Bronner et al., Bcl-2 protooncogene and the gastrointestinal mucosal epithelial tumor progression model as related to proposed morphologic and molecular sequences. Lab. Invest. 1993, 68:43A					
	AP	Brooks et al., Requirement of vascular integrin alpha v beta 3 for angiogenesis. Science. 1994 April 22;264(5158):569-71.					
	AQ	Buchwald et al., Long-term, continuous intravenous heparin administration by an implantable infusion pump in ambulatory patients with recurrent venous thrombosis. Surgery. 1980 Oct;88(4):507-16					
	AR	Campos et al., "High expression of bcl-2 protein in acute myeloid leukemia is associated with poor response to chemotherapy." Blood 1993, 81:3091-6					
	AS	Cancer: Principles & Practice of Oncology, DeVita, Jr., Hellman and Rosenberg (eds.) 2 <sup>nd</sup> edition, Philadelphia, PA :J.B. Lippincott Co., 1985					
	AT	Cao, Endogenous angiogenesis inhibitors: angiostatin, endostatin, and other proteolytic fragments. Prog Mol Subcell Biol. 1998, 20:161-76					

	AU	Chapman et al., Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma. <i>J. Clin. Oncol.</i> 1999, 17(9):2745-51
	AV	Chen et al., Determination of N(G),N(G)-dimethylarginine in human plasma by high-performance liquid chromatography. <i>J Chromatogr B Biomed Sci Appl.</i> 1997, May 9; 692(2):467-71
	AW	Chi-Hong et al., Nuclease activity of 1,10-phenanthroline-copper: sequence-specific targeting. <i>Proc Natl Acad Sci</i> 1986, Oct;83(19):7147-51
	AX	Chu et al., Nonenzymatic sequence-specific cleavage of single-stranded DNA. <i>Proc Natl Acad Sci.</i> 1985, Feb;82(4):963-7
	AY	<i>Controlled Drug Bioavailability, Drug Product Design and Performance</i> , Smolen and Ball (eds.), Wiley: New York (1984)
	AZ	Cotter et al., Antisense oligonucleotides suppress B-cell lymphoma growth in a SCID-hu mouse model. <i>Oncogene.</i> 1994, Oct;9(10):3049-55
	BA	Croce et al., Molecular basis of human B and T cell neoplasia. <i>Advance in Viral Oncology</i> , G. Klein(ed.), New York, Raven Press. 1987, 7:35-51
	BB	Crowley et al., Prevention of metastasis by inhibition of the urokinase receptor. <i>Proc Natl Acad Sci</i> 1993, Jun 1;90(11):5021-5
	BC	Egholm et al., 1992, <i>Peptide Nucleic Acids (PNA)-Oligonucleotide Analogues With An Achiral Peptide Backbone</i> . <i>J Am. Chem. Soc</i> 1992, 114:1895-97
	BD	Goodchild, Conjugates of oligonucleotides and modified oligonucleotides: a review of their synthesis and properties, <i>Bioconjug. Chem.</i> 1990, 1(3):165-87
	BE	Goodson, 1984, "Dental Applications" in <i>Medical Applications of Controlled Release</i> , vol. 2, pp. 115-138
	BF	Grover et al., Bcl-2 expression in malignant melanoma and its prognostic significance <i>Eur. J. Surg. Oncol.</i> 1996, 22(4):347-9
	BG	Haldar et al., The bcl-2 gene encodes a novel G protein. <i>Nature.</i> 1989 Nov 9;342(6246):195-8
	BH	Holt, et al., An oligomer complementary to c-myc mRNA inhibits proliferation of HL-60 promyelocytic cells and induces differentiation. <i>Mol Cell Biol.</i> 1988 Feb;8(2):963-73
	BI	Jansen et al., "Bcl-2 antisense therapy chemosensitizes human melanoma in SCID mice" <i>Nat. Med.</i> 1998, 4(2):232-4
	BJ	Kitada et al., Reversal of chemoresistance of lymphoma cells by antisense-mediated reduction of bcl-2 gene expression. <i>Antisense Res Dev.</i> 1994 Summer;4(2):71-9
	BK	Kitada et al., Investigations of antisense oligonucleotides targeted against bcl-2 RNAs. <i>Antisense Res Dev.</i> 1993 Summer;3(2):157-69
	BL	Knorre et al., Reactive oligonucleotide derivatives and sequence-specific modification of nucleic acids. <i>Biochimie.</i> 1985 Jul-Aug;67(7-8):785-9
	BM	Langer and Peppas, 1981 "Present and Future Applications of Biomaterials in Controlled Drug Delivery Systems", <i>J. Biomaterials</i> 2(3):201-14
	BN	Langer, New methods of drug delivery. <i>Science.</i> 1990 Sep 28;249(4976):1527-33
	BO	Lu et al., "Bcl-2 protooncogene expression in Epstein Barr Virus-associated nasopharyngeal carcinoma." <i>Int. J. Cancer</i> 1993, 53:29-35
	BP	McDonnell et al., Expression of the protooncogene bcl-2 and its association with emergence of androgen-independent prostate cancer. <i>Cancer Res.</i> 1992, 52:6940-4

	BQ	Min et al., Urokinase receptor antagonists inhibit angiogenesis and primary tumor growth in syngeneic mice. Cancer Res. 1996 May 15;56(10):2428-33
	BR	Miyashita et al., bcl-2 gene transfer increases relative resistance of S49.1 and WEHI7.2 lymphoid cells to cell death and DNA fragmentation induced by glucocorticoids and multiple chemotherapeutic drugs. Cancer Res. 1992 Oct 1;52(19):5407-11
	BS	Miyashita et al., Bcl-2 oncprotein blocks chemotherapy-induced apoptosis in a human leukemia cell line. Blood. 1993 Jan 1;81(1):151-7
	BT	Monia et al., Evaluation of 2'-modified oligonucleotides containing 2' deoxy gaps as antisense inhibitors of gene expression, J. Biol. Chem. 1993, 268:14514-22
	BU	Morvan et al., alpha-DNA. I. Synthesis, characterization by high field 1H-NMR, and base-pairing properties of the unnatural hexadeoxyribonucleotide alpha-[d(CpCpTpTpCpC)] with its complement beta-[d(GpGpApApGpG)]. Nucleic Acids Res. 1986 Jun 25;14(12):5019-35
	BV	Negrini et al., Molecular analysis of mbcl-2: structure and expression of the murine gene homologous to the human gene involved in follicular lymphoma. Cell. 1987 May 22;49(4):455-63
	BW	Paoletti C. Anti-sense oligonucleotides as potential antitumour agents: prospective views and preliminary results. Anticancer Drug Des. 1988 Mar;2(4):325-31
	BX	<i>Physicians' Desk Reference</i> , 54 <sup>th</sup> Edition (2000)
	BY	Raynaud et al., Pharmacokinetics of G3139, a phosphorothioate oligodeoxynucleotide antisense to bcl-2, after intravenous administration or continuous subcutaneous infusion to mice. J Pharmacol Exp Ther. 1997 Apr;281(1):420-7
	BZ	Reed, Regulation of apoptosis by bcl-2 family proteins and its role in cancer and chemoresistance Curr. Opin. Oncol. 1995, 7:541-6
	CA	Reed et al., Regulation of chemoresistance by the bcl-2 oncprotein in non-Hodgkin's lymphoma and lymphocytic leukemia cell lines. Ann Oncol. 1994;5 Suppl 1:61-5
	CB	Reed et al., Antisense-mediated inhibition of BCL2 protooncogene expression and leukemic cell growth and survival: comparisons of phosphodiester and phosphorothioate oligodeoxynucleotides. Cancer Res. 1990 Oct 15;50(20):6565-70
	CC	Reed et al., "Differential expression of bcl-2 protooncogene in neuroblastoma and other human tumor cell lines of neural origin." Cancer Res. 1991 51:6529-38
	CD	Reed et al., BCL2-mediated tumorigenicity of a human T-lymphoid cell line: synergy with MYC and inhibition by BCL2 antisense. Proc Natl Acad Sci 1990 May;87(10):3660-4
	CE	Reed et al., Regulation of bcl-2 proto-oncogene expression during normal human lymphocyte proliferation. Science. 1987 Jun 5;236(4806):1295-9
	CF	Selzer et al., Expression of Bcl-2 family members in human melanocytes, in melanoma metastases and in melanoma cell lines. Melanoma Res. 1998 Jun;8(3):197-203
	CG	Stein et al., Oligodeoxynucleotides as inhibitors of gene expression: a review. Cancer Res. 1988 May 15;48(10):2659-68.
	CH	Stein et al., Physicochemical properties of phosphorothioate oligodeoxynucleotides. Nucleic Acids Res. 1988 Apr 25;16(8):3209-21
	CI	Strasser et al., bcl-2 transgene inhibits T cell death and perturbs thymic self-censorship. Cell. 1991 Nov 29;67(5):889-99

	CJ	Stull et al., Antigene, ribozyme and aptamer nucleic acid drugs: progress and prospects. Pharm Res. 1995 Apr;12(4):465-83
	CK	Treat et al., 1989, "Liposome Encapsulated Doxorubicin Preliminary Results of Phase I and Phase II Trials" in <i>Liposomes in the Therapy of Infectious Disease and Cancer</i> , Lopez-Berestein and Fidler (eds.), Liss, New York, pp. 353-65
	CL	Tsujimoto et al., Involvement of the bcl-2 gene in human follicular lymphoma. Science 1985, 228:1440-1443
	CM	Uhlmann et al., EMD 53998 acts as Ca(2+)-sensitizer and phosphodiesterase III-inhibitor in human myocardium. Basic Res Cardiol. 1995 Sep-Oct;90(5):365-71
	CN	Vlassov et al., Complementary addressed modification and cleavage of a single stranded DNA fragment with alkylating oligonucleotide derivatives. Nucleic Acids Res. 1986 May 27;14(10):4065-76
	CO	Waters et al., Phase I clinical and pharmacokinetic study of bcl-2 antisense oligonucleotide therapy in patients with non-Hodgkin's lymphoma. J Clin Oncol. 2000 May;18(9):1812-23
	CP	Webb et al., BCL-2 antisense therapy in patients with non-Hodgkin lymphoma. Lancet. 1997 Apr 19;349(9059):1137-41
	CQ	Webb et al., Hybridization triggered cross-linking of deoxyoligonucleotides. Nucleic Acids Res. 1986 Oct 10;14(19):7661-74
	CR	Wickstrom et al., Human promyelocytic leukemia HL-60 cell proliferation and c-myc protein expression are inhibited by an antisense pentadecadeoxynucleotide targeted against c-myc mRNA. Proc Natl Acad Sci 1988 Feb;85(4):1028-32
	CS	Williams, Programmed cell death: apoptosis and oncogenesis. Cell. 1991 Jun 28;65(7):1097-8
	CT	Yunis et al., Bcl-2 and other genomic alterations in the prognosis of large-cell lymphomas. N. Engl. J. Med. 1989, 320:1047-54
	CU	Zamecnik et al., Inhibition of replication and expression of human T-cell lymphotropic virus type III in cultured cells by exogenous synthetic oligonucleotides complementary to viral RNA. Proc Natl Acad Sci 1986 Jun;83(12):4143-6
	CV	Zamecnik and Stephenson, Inhibition of Rous sarcoma virus replication and cell transformation by a specific oligodeoxynucleotide. Proc Natl Acad Sci 1978 Jan;75(1):280-4

EXAMINER

DATE CONSIDERED

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.